Angiotensin-(1-7) attenuates the anxiety and depression-like behaviors in transgenic rats with low brain angiotensinogen

Behavioural Brain Research

Volumn 257, Issue , 2013, Pages 25-30

  Kangussu, Lucas M ^a   Almeida Santos, Ana F ^a   Bader, Michael ^b   Alenina, Natalia ^b   Fontes, Marco AntÔnio P ^a   Santos, Robson A S ^a   Aguiar, Daniele C ^a   Campagnole Santos, Maria José ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Angiotensin (1 7); Anxiety; Depression; Fluoxetine; Low brain angiotensinogen transgenic rats

Indexed keywords

ANGIOTENSIN 5; ANGIOTENSIN 6; ANGIOTENSIN 7; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSINOGEN; FLUOXETINE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BRAIN LATERAL VENTRICLE; CONTROLLED STUDY; DEPRESSION; FORCED SWIMMING TEST; IMMOBILITY; MALE; MAZE TEST; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

ANGIOTENSIN-(1-7); ANXIETY; DEPRESSION; FLUOXETINE; LOW BRAIN ANGIOTENSINOGEN TRANSGENIC RATS;

ANGIOTENSIN I; ANGIOTENSINOGEN; ANIMALS; ANXIETY; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION ROUTES; FLUOXETINE; MALE; MAZE LEARNING; PEPTIDE FRAGMENTS; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RNA, ANTISENSE; SEROTONIN UPTAKE INHIBITORS; SWIMMING;

EID: 84885219754     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.09.003     Document Type: Article

References (58)

1. Lavoie J.L., Sigmund C.D. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 2003, 144:2179-2183.
2. Phillips M.I., Sumners C. Angiotensin II in central nervous system physiology. Regul Pept 1998, 78:1-11.
3. Ferreira A.J., Murca T.M., Fraga-Silva R.A., Castro C.H., Raizada M.K., Santos R.A. New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012, 2012:147825.
4. Campagnole-Santos M.J., Heringer S.B., Batista E.N., Khosla M.C., Santos R.A. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol 1992, 263(1 Pt 2):R89-R94.
5. von Bohlen und Halbach O., Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 2006, 326:599-616.
6. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010, 50:439-465.
7. Becker L.K., Etelvino G.M., Walther T., Santos R.A., Campagnole-Santos M.J. Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. Am J Physiol (Heart Circ Physiol) 2007, 293:H1416-H1424.
8. Costa A.C., Becker L.K., Moraes E.R., Romero T.R., Guzzo L., Santos R.A., et al. Angiotensin-(1-7) induces peripheral antinociception through mas receptor activation in an opioid-independent pathway. Pharmacology 2012, 89:137-144.
9. Lazaroni T.L., Raslan A.C., Fontes W.R., de Oliveira M.L., Bader M., Alenina N., et al. Angiotensin-(1-7)/Mas axis integrity is required for the expression of object recognition memory. Neurobiol Learn Mem 2012, 97:113-123.
10. Voigt J.P., Hortnagl H., Rex A., van Hove L., Bader M., Fink H. Brain angiotensin and anxiety-related behavior: the transgenic rat TGR(ASrAOGEN)680. Brain Res 2005, 1046:145-156.
11. Xing J., Kong J., Lu J., Li J. Angiotensin-(1-7) inhibits neuronal activity of dorsolateral periaqueductal gray via a nitric oxide pathway. Neurosci Lett 2012, 522:156-161.
12. Georgiev V., Stancheva S., Kambourova T., Getova D. Effect of angiotensin II on the Vogel conflict paradigm and on the content of dopamine and noradrenaline in rat brain. Acta Physiol Pharmacol Bulg 1990, 16:32-37.
13. Belcheva I., Georgiev V., Chobanova M., Hadjiivanova C. Behavioral effects of angiotensin II microinjected into CA1 hippocampal area. Neuropeptides 1997, 31:60-64.
14. Kaiser F.C., Palmer G.C., Wallace A.V., Carr R.D., Fraser-Rae L., Hallam C. Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. Neuroreport 1992, 3:922-924.
15. Giardina W.J., Ebert D.M. Positive effects of captopril in the behavioral despair swim test. Biol Psychiatry 1989, 25:697-702.
16. Gard P.R. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002, 438:1-14.
17. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003, 100:8258-8263.
18. Walther T., Voigt J.P., Fink H., Bader M. Sex specific behavioural alterations in Mas-deficient mice. Behav Brain Res 2000, 107:105-109.
19. Bild W., Ciobica A. Angiotensin-(1-7) central administration induces anxiolytic-like effects in elevated plus maze and decreased oxidative stress in the amygdala. J Affect Disord 2013, 145:165-171.
20. Schinke M., Baltatu O., Bohm M., Peters J., Rascher W., Bricca G., et al. Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Proc Natl Acad Sci USA 1999, 96:3975-3980.
21. Gomes da Silva A.Q., Xavier C.H., Campagnole-Santos M.J., Caligiorne S.M., Baltatu O.C., Bader M., et al. Cardiovascular responses evoked by activation or blockade of GABA(A) receptors in the hypothalamic PVN are attenuated in transgenic rats with low brain angiotensinogen. Brain Res 2012, 1448:101-110.
22. Graeff F.G. Minor tranquilizers and brain defense systems. Braz J Med Biol Res 1981, 14:239-265.
23. Graeff F.G. Role of 5-HT in defensive behavior and anxiety. Rev Neurosci 1993, 4:181-211.
24. Graeff F.G. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz J Med Biol Res 1994, 27:811-829.
25. Graeff F.G. Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev 2004, 28:239-259.
26. Hensman R., Guimaraes F.S., Wang M., Deakin J.F. Effects of ritanserin on aversive classical conditioning in humans. Psychopharmacology (Berl) 1991, 104:220-224.
27. Handley S.L., McBlane J.W. 5HT drugs in animal models of anxiety. Psychopharmacology (Berl) 1993, 112:13-20.
28. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 1995, 65:319-395.
29. McNaughton N., Gray J.A. Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 2000, 61:161-176.
30. Zangrossi H., Viana M.B., Zanoveli J., Bueno C., Nogueira R.L., Graeff F.G. Serotonergic regulation of inhibitory avoidance and one-way escape in the rat elevated T-maze. Neurosci Biobehav Rev 2001, 25:637-645.
31. Joca S.R., Guimaraes F.S. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 2006, 185:298-305.
32. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press, New York. 3rd ed.
33. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol 1984, 327:1-5.
34. Aguiar D.C., Terzian A.L., Guimaraes F.S., Moreira F.A. Anxiolytic-like effects induced by blockade of transient receptor potential vanilloid type 1 (TRPV1) channels in the medial prefrontal cortex of rats. Psychopharmacology (Berl) 2009, 205:217-225.
35. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002, 23:238-245.
36. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
37. Costall B., Domeney A.M., Gerrard P.A., Horovitz Z.P., Kelly M.E., Naylor R.J., et al. Effects of captopril and SQ29,852 on anxiety-related behaviours in rodent and marmoset. Pharmacol Biochem Behav 1990, 36:13-20.
38. Gard P.R. Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression. Expert Opin Ther Targets 2004, 8:7-14.
39. Okuyama S., Sakagawa T., Chaki S., Imagawa Y., Ichiki T., Inagami T. Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res 1999, 821:150-159.
40. Walther T., Balschun D., Voigt J.P., Fink H., Zuschratter W., Birchmeier C., et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem 1998, 273:11867-11873.
41. Voigt J.P., Rex A., Sohr R., Fink H. Hippocampal 5-HT and NE release in the transgenic rat TGR(mREN2)27 related to behavior on the elevated plus maze. Eur Neuropsychopharmacol 1999, 9:279-285.
42. Slattery D.A., Cryan J.F. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 2012, 7:1009-1014.
43. Deicken R.F. Captopril treatment of depression. Biol Psychiatry 1986, 21:1425-1428.
44. Germain L., Chouinard G. Treatment of recurrent unipolar major depression with captopril. Biol Psychiatry 1988, 23:637-641.
45. Saab Y.B., Gard P.R., Yeoman M.S., Mfarrej B., El-Moalem H., Ingram M.J. Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1113-1118.
46. Kohara K., Brosnihan K.B., Ferrario C.M. Angiotensin(1-7) in the spontaneously hypertensive rat. Peptides 1993, 14:883-891.
47. Martin P., Massol J., Puech A.J. Captopril as an antidepressant? Effects on the learned helplessness paradigm in rats. Biol Psychiatry 1990, 27:968-974.
48. Gard P.R., Mandy A., Sutcliffe M.A. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry 1999, 45:1030-1034.
49. Gard P.R., Mandy A., Whiting J.M., Nickels D.P., Meakin A.J. Reduction of responses to angiotensin II by antidepressant drugs. Eur J Pharmacol 1994, 264:295-300.
50. Nahmod V.E., Finkielman S., Benarroch E.E., Pirola C.J. Angiotensin regulates release and synthesis of serotonin in brain. Science 1978, 202:1091-1093.
51. Ball S.G., Kuhn A., Wall D., Shekhar A., Goddard A.W. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005, 66:94-99.
52. Bruce S.E., Vasile R.G., Goisman R.M., Salzman C., Spencer M., Machan J.T., et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia. Am J Psychiatry 2003, 160:1432-1438.
53. Drapier D., Bentue-Ferrer D., Laviolle B., Millet B., Allain H., Bourin M., et al. Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Behav Brain Res 2007, 176:202-209.
54. Mathew S.J., Price R.B., Charney D.S. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet 2008, 148:89-98.
55. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002, 17(Suppl. 3):294-299.
56. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998, 59(Suppl. 14):11-14.
57. Mandrioli R., Mercolini L., Saracino M.A., Raggi M.A. Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2012, 19:1846-1863.
58. Reneric J.P., Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998, 136:190-197.